http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#Head http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#assertion http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#provenance http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#pubinfo http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#assertion http://purl.obolibrary.org/obo/DOID_9182 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_9182 http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00635 http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#association http://www.w3.org/2000/01/rdf-schema#label indications and usage prednisone tablets are indicated in the following conditions endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance rheumatic disorders as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in collagen diseases during an exacerbation or as maintenance therapy in selected cases of dermatologic diseases pemphigus allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as respiratory diseases symptomatic sarcoidosis hematologic disorders idiopathic thrombocytopenic purpura in adults neoplastic diseases for palliative management of edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus gastrointestinal diseases to tide the patient over a critical period of the disease in nervous system acute exacerbations of multiple sclerosis miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00635 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#provenance http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#pubinfo http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#sig http://purl.org/nanopub/x/hasSignature DSNXiRHQAV3QW5w0L5ScJppgwJ4nluer4DMoeCICFAFSLguWlIpxPTx5sV2svKldjvrgqzrtfgjWmBfxVh586If5VQLX/xEveQuPacWmCVW37XMSSWXi0/I1MpiRjYr0j+9ZkX+/HigjoexfsGkmtzw3MQ8UhyU4xD/g8mVnBdE= http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ http://purl.org/dc/terms/created 2021-06-13T12:54:01.486+02:00 http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAwEdIq016WJVmWn0x_bXClDggAoT2oed3bIV4DLuRUQQ https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs